SCHEMBL20782835

SCHEMBL20782835

O=C(NCCC1CCNCC1)OCc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
ITGB3 P05106 7/20 0.54
ITGA2B P08514 7/20 0.54
IDO1 P14902 1/20 0.54
TDO2 P48775 1/20 0.54
HTT P42858 1/20 0.53
ITGAV P06756 1/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
GAA P10253 1/20 0.51
TPSAB1 Q15661 1/20 0.51
TPSD1 Q9BZJ3 1/20 0.51
TPSG1 Q9NRR2 1/20 0.51
ALDH1A1 P00352 1/20 0.49
TGM2 P21980 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28895096 0.99 LMNA (0.55) LMNASMN1; SMN2ITGB3ITGA2BIDO1
SCHEMBL30500860 0.95 MEN1 (0.52) LMNASMN1; SMN2ITGB3ITGA2BIDO1
SCHEMBL30500863 0.92 HTT (0.58) LMNASMN1; SMN2ITGB3ITGA2BIDO1
SCHEMBL19083306 0.92 LMNA (0.53) LMNASMN1; SMN2ITGB3ITGA2BIDO1
SCHEMBL8396587 0.90 LMNA (0.63) LMNASMN1; SMN2IDO1TDO2HTT
SCHEMBL8396013 0.88 LMNA (0.60) LMNASMN1; SMN2IDO1TDO2HTT
SCHEMBL8391394 0.88 MEN1 (0.63) LMNASMN1; SMN2IDO1TDO2HTT
SCHEMBL21248691 0.88 LMNA (0.60) LMNASMN1; SMN2IDO1TDO2HTT
SCHEMBL30267102 0.87 ITGB3 (0.48) LMNASMN1; SMN2ITGB3ITGA2BITGAV
SCHEMBL8393628 0.86 MEN1 (0.65) LMNASMN1; SMN2IDO1TDO2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4263547-B1 DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARM SPA (IT) 2025-07-02 EP disclosed
US-20240082223-A1 DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-03-14 US disclosed
EP-4263547-A1 DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2023-10-25 EP disclosed
CN-116600810-A Dihydrofuranopyridine derivatives as RHO-kinase inhibitors 奇斯药制品公司 2023-08-15 CN disclosed
US-20230183239-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF ABBVIE INC (US) 2023-06-15 US disclosed
WO-2022128853-A1 DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-06-23 WO disclosed
US-20200291024-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF ABBVIE INC (US) 2020-09-17 US disclosed
WO-2019046778-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF MAVUPHARMA, INC. (US) 2019-03-07 WO disclosed
CN-107074821-A It is used as the diamines macrocyclic compound of FXIA inhibitor 百时美施贵宝公司 2017-08-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200291024-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF ENPP1, ENPP3, STING1 LMNA 3502/4885SMN1; SMN2 3306/4885ITGB3 3882/4885
US-20240082223-A1 DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS ROCK1, ROCK2, RHOA LMNA 3275/4885SMN1; SMN2 4674/4885ITGB3 3054/4885
US-20230183239-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF ENPP1, ENPP3, STING1 LMNA 3502/4885SMN1; SMN2 3306/4885ITGB3 3882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.